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Abstract
Background: Cryoglobulins are cold-precipitable immunoglobulins that may cause systemic vasculitis including
cryoglobulinaemic glomerulonephritis (CGN). Type 1 cryoglobulins consist of isolated monoclonal immunoglobulin
(mIg), whereas mixed cryoglobulins are typically immune complexes comprising either monoclonal (type 2) or
polyclonal (type 3) Ig with rheumatoid activity against polyclonal IgG. Only CGN related to type 1 cryoglobulins has
been clearly associated with monoclonal gammopathy of undetermined significance (MGUS) using the
conventional serum-, urine- or tissue-based methods of paraprotein detection.
Case presentation: We present four patients with noninfectious mixed (type 2 or 3) CGN and MGUS. Two patients
had type 2 cryoglobulinaemia, one had type 3 cryoglobulinaemia, and one lacked definitive typing of the serum
cryoprecipitate. The serum monoclonal band was IgM-κ in all four cases. Treatments included corticosteroids,
cyclophosphamide, plasma exchange, and rituximab. At median 3.5 years’ follow-up, no patient had developed a
haematological malignancy or advanced chronic kidney disease. Other potential causes of mixed cryoglobulinaemia
were also present in our cohort, notably primary Sjögren’s syndrome in three cases.
Conclusion: Our study raises questions regarding the current designation of type 2 CGN as a monoclonal
gammopathy of renal significance, and the role of clonally directed therapies for noninfectious mixed CGN outside
the setting of haematological malignancy.
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Background
Cryoglobulinaemia is defined by the presence of circulat-
ing immunoglobulin (Ig) that aggregates in vitro at tem-
peratures < 37 °C, and redissolves on rewarming [1]. For
cryoglobulinaemia to be detected, blood sampling, clot-
ting and serum separation by centrifugation must ideally
be performed at 37 °C, before serum storage at 4 °C for
up to 7 days [2]. Any significant cryoprecipitate (usually
> 0.05 g/L or cryocrit > 1%) may then be quantified and
analyzed by electrophoresis and immunofixation after
washing and redissolving at 37 °C. The classification sys-
tem for cryoglobulinaemia devised by Brouet and col-
leagues distinguishes three main types [3]. Type 1
cryoglobulins consist of monoclonal Ig (mIg) or biclonal
Ig, and occur in patients with clonal B cell or plasma cell
disorders [4]. So-called ‘mixed’ cryoglobulins are
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considered as immune complexes typically comprising
either monoclonal (type 2) or polyclonal (type 3) Ig
(mostly IgM) with rheumatoid factor activity against the
Fc portion of polyclonal IgG. Infections are the com-
monest cause of mixed cryoglobulinaemia, notably hepa-
titis C virus (HCV) [5] and hepatitis B virus (HBV) [6],
together with human immunodeficiency virus (HIV) and
numerous other viral, bacterial, parasitic and fungal in-
fections [1, 7]. Noninfectious causes of mixed cryoglobu-
linaemia include autoimmune diseases, especially
primary Sjögren’s syndrome (pSS) [8], and the malignant
clonal disorders [9].
There is some uncertainty as to whether cryoglobulins
are truly pathogenic in vivo, given that disease manifes-
tations including systemic vasculitis occur in only a mi-
nority of patients with detectable cryoglobulinaemia
[10]. The systemic vasculitis of cryoglobulinaemia is ex-
emplified by cryoglobulinaemic glomerulonephritis
(CGN), which can be classified as type 1 or mixed ac-
cording to which type of cryoglobulin is found in associ-
ation. Classic renal histological features of CGN,
including membranoproliferative glomerulonephritis
(MPGN), intracapillary ‘pseudothrombi’, crescents and
small vessel vasculitis are fairly nonspecific [11]. On the
other hand, the impression that renal causation is dir-
ectly attributable to glomerular deposition of cryoglobu-
lins may be strengthened by electron microscopy (EM)
showing curvilinear microtubules, suggestive of aggre-
gated cryoglobulins [12, 13], or immunohistochemistry
showing light chain restriction of pseudothrombi in the
case of type 1 CGN [14, 15].
Monoclonal gammopathy is diagnosed when mIg
secreted into the circulation by a proliferating clone
of plasma cells or B cells is detected by means of
serum protein electrophoresis (SPEP), immunofixation
(SIFE) or free light chain assays (SFLC), or urine pro-
tein electrophoresis (UPEP) or immunofixation (UIFE)
[16]. Further evaluation is often required for one or
other of the malignant clonal disorders, which include
multiple myeloma, Waldenström’s macroglobulinae-
mia, B cell lymphoma and chronic lymphocytic
leukemia. However, in most patients, monoclonal
gammopathy of undetermined significance (MGUS) or
another pre-malignant condition is diagnosed. Previ-
ous studies have established a clear association of
type 1 CGN not only with malignant clonal disorders,
but also with MGUS [14, 17–20]. This has led to the
inclusion of type 1 CGN within the disease classifica-
tion of monoclonal gammopathy of renal significance
(MGRS) [21–23]. This term recognizes that certain
renal lesions may be the result of nephrotoxic mIg
produced by small (i.e. pre-malignant) plasma cell or
B cell clones, with confirmation in many cases based
on light chain restricted renal staining [24].
We undertook this study in our patient cohort to as-
sess whether mixed (type 2 or 3) CGN is also sometimes
diagnosed in patients with MGUS, as noted above for
type 1 CGN. Our investigation was prompted by the sur-
prising inclusion of type 2 CGN within the MGRS dis-
ease classification [21–23], despite having only a very
weak association with MGUS in the published medical
literature, and the inability to confirm light chain restric-
tion of renal tissue owing to the polyclonal Ig compo-
nent of type 2 cryoglobulins [11]. We included cases for
the period 2002–2019 in which renal histology was com-
patible with CGN, with cryoglobulinaemia (> 0.05 g/L)
and the detection of a serum monoclonal band based on
SPEP/SIFE. Patients were excluded where type 1 cryo-
globulinaemia was confirmed on immunofixation of the
cryoprecipitate and/or light chain restricted staining (as
assessed by immunofluorescent staining of paraffin-
embedded tissue after protease digestion (paraffin-IF)
[25]). Patients with a malignant clonal disorder were also
excluded (with a minimum requirement in our study for
bone marrow aspirate and trephine (BMAT) with flow
cytometry of the aspirate and/or peripheral blood, and
computed tomography with positron emission tomog-
raphy (CT-PET)). Finally, patients with a potential infec-
tious aetiology for mixed cryoglobulinaemia were
excluded (with a minimum requirement for blood cul-
tures, HBV surface antigen, and HBV core, HCV, and
HIV antibodies), as were those in whom vasculitis was
potentially due to recognised causes other than cryoglo-
bulinaemia (based on serologies comprising at a mini-
mum anti-neutrophil cytoplasmic, anti-glomerular
basement membrane, anti-double stranded DNA, anti-
U1-ribonucleoprotein and anti-cardiolipin antibodies,
and lupus anticoagulant).
Case presentation
Of twenty patients at our hospital with noninfectious
mixed CGN in whom SPEP/SIFE was performed, we
present four cases with confirmed MGUS, including
three females and one male (Table 1). Median age at
presentation was 54 years (range 47–66 years). All pa-
tients had microscopic haematuria and proteinuria, with
a median urinary protein creatinine ratio (uPCR) of 106
mg/mmol (range 70-134mg/mmol). Renal function was
significantly impaired in three of the four patients, with
a median serum creatinine overall of 221 μmol/L (range
80-292 μmol/L) and eGFR of 27 mL/min per 1.73m2
(range 15-70 mL/min per 1.73m2, MDRD). All patients
had mildly reduced serum albumin levels, and serum
complement C4 ± C3 levels were low in three patients.
All three female patients had previously been diagnosed
with pSS and showed seropositivity for antinuclear, SSA/
Ro and SSB/La antibodies. In the weeks following
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Table 1 Demographic and renal clinical features at time of renal biopsy
Patient Age
(Years)
Sex Extrarenal clinical
features
Comorbid
conditions
Urine studies Serum studies
Red
cells
PCR (< 30
mg/mmol)
ACR (< 3.5
mg/mmol)
Creatinine
(μmol/L)
eGFR (mL/
min per
1.73 m2)a
Albumin
(3.5-5 g/dL)
C3
(0.9–1.8 g/L)
C4
(0.16–0.5 g/L)
ANA/SSA/
SSB
1 47 F Purpura, arthritis pSS Pos 70 33 256 18 2.6 0.46 < 0.03 Pos
2 60 F Purpura, benign
lymphadenopathy
pSS, CC Pos 126 75 292 15 3.2 1.1 0.27 Pos
3 66 M – – Pos 86 55 186 35 2.7 0.76 < 0.03 Neg
4 47 F Purpura, arthritis pSS,
hypoGG
Pos 134 – 80 70 3.1 1.27 < 0.03 Pos
PCR protein creatinine ratio; ACR albumin creatinine ratio; eGFR estimated glomerular filtration rate; ANA antinuclear antibody; SSA anti-Ro; SSB anti-La; pSS primary
Sjögren’s syndrome; CC cholangiocarcinoma; hypoGG hypogammaglobulinaemia
a Modified diet in renal disease (MDRD)
Fig. 1 Histology. Light microscopy in patient 1 with a periodic acid-Schiff (PAS) stain and b silver stain showing MPGN with double contours and
striking intraluminal, PAS-positive pseudothrombi. Equal (+++) intensity of paraffin-IF staining of pseudothrombi for c κ and d λ light chain. In
patient 2, e silver stain showing a small cellular crescent with necrosis, and f haematoxylin and eosin stain of a small artery with concentric
intimal arteritis. Magnification ×40
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diagnosis of CGN, Patient 2 underwent laparotomy for
an incidental finding of cholangiocarcinoma.
Renal biopsy revealed histological features of CGN in
all four patients (Fig. 1 and Table 2). These included
MPGN in three patients, cellular crescents with arteri-
olar necrosis and thrombosis in one patient, and intraca-
pillary pseudothrombi in three patients. Interstitial
fibrosis ≥25% with mild glomerulosclerosis was also
present in three cases. Immunohistochemistry showed
variable IgG, IgM and C3 staining in capillary loops and
the mesangium, with IgM and/or IgG staining of pseu-
dothrombi in two cases. No case showed light chain re-
striction on paraffin-IF. EM was performed in three
cases, revealing intracapillary curvilinear deposits in one
case and unstructured glomerular deposits in the other
two cases.
Serum biochemistry at presentation (Table 3) included
a median cryoglobulin concentration of 0.43 g/L (range
0.1–0.62 g/L) in three cases, with a cryocrit of 9% in the
fourth case. Immunofixation of the cryoprecipitate con-
firmed type 2 cryoglobulinaemia with a monoclonal
IgM-κ component in two patients and type 3 cryoglobu-
linaemia in one patient, and was not performed in the
remaining patient. SPEP revealed generally small mono-
clonal bands of median concentration < 1 g/L (range < 1
- 2 g/L). In all four cases, the paraprotein was IgM-κ,
with an IgG-κ paraprotein also present in one case (Pa-
tient 2). No patient showed bone marrow evidence of a
malignant plasma cell or B cell disorder (Table 4).
Treatment consisted of corticosteroids in all patients,
cyclophosphamide in three patients, plasma exchange in
three patients, and rituximab in two patients, one of
whom (Patient 4) later received maintenance therapy for
a diagnosis of seronegative lupus nephritis with myco-
phenolate mofetil (Table 5). At a median follow-up of
3.5 years (range 1.5–11 years), no patient had developed
a malignant clonal disorder or end-stage renal failure, or
was deceased. Renal parameters were improved in all
cases but one (Patient 4), with a median uPCR at last
follow-up of 103 mg/mmol (range 24 – 302 mg/mmol),
serum creatinine of 133 μmol/L (range 62 - 168 μmol/L),
and eGFR of 45 mL/min per 1.73m2 (range 30-90 mL/
min per 1.73m2). Serum C4 remained undetectable in
two patients. Cryoglobulinaemia was undetectable at last
follow up in all four patients, and SPEP/UPEP was
negative. However, SIFE revealed an IgM-κ paraprotein
Table 2 Renal histology
Patient No glomeruli
(No globally
sclerosed)
Pattern of
glomerular
inflammation
Arteriolar
necrosis,
thrombosis
Interstitial
inflammatory
infiltrate
Interstitial
fibrosis (< 5%)
Pseudothrombi Glomerular IHC (paraffin-IF) Deposits
on EM
1 25 (0) Early MPGN No Patchy, mild < 5% Yes Loop focal IgM+ (κ-, λ-)
Pseudothrombi IgG+,
IgM+++ (κ+++, λ+++)
Unstructured
2 18 (6) Crescents (5
cellular, 1 fibro-
cellular, 2 fibrous)
Yes Light, chronic 40% No Mesangial focal IgM++,
C3++ (κ+, λ+)
–
3 20 (5) MPGN,
endocapillary
(CD68+)
No Light, chronic 25% Yes Loop and pseudothrombi
IgG++, IgM+++, IgA+,
C3+++, C1q++ (κ ++, λ ++)
Unstructured
4 18 (2) MPGN No Moderate 25% Sparse Mesangial and loop IgG+,
IgM++, IgA+, C3++ (κ -, λ -)
Fine
curvilinear
MPGN membranoproliferative glomerulonephritis; IHC immunohistochemistry; IF immunofluorescence; IF electron microscopy; κ kappa; λ lambda
Table 3 Biochemistry at time of renal biopsy
Patient Serum cryoglobulin Paraprotein Peripheral
blood flow
cytometry
Concentration
(g/L)
Type RF SPEP
(g/L)
SIFE SFLCa Spot UPEP/
UIFEκ (3.3–19.4 mg/L) λ (5.7–26.3 mg/L) κ /λ (0.26–1.65)
1 0.1 2 or 3 Neg 2 IgM-κ 26.6 5.5 4.84 Neg Normal
2 0.43 2 (mIgM-κ +
pIgG)
Pos < 1 IgM-κ, IgG-κ 231.9 65.3 3.55 Neg Normal
3 0.62 3 (pIgM +
pIgG)
Pos < 1 IgM-κ 49.0 27.5 1.78 Neg Not assessed
4 9% cryocrit 2 (mIgM-κ +
pIgG)
Pos < 1 IgM-κ 157.0 17.4 9.02 IgM-κ Normal
RF rheumatoid factor; SPEP serum protein electrophoresis; SIFE serum immunofixation; SFLC serum free light chains; κ kappa; λ lambda; UPEP/UIFE urine protein
electrophoresis/immunofixation; mIg monoclonal immunoglobulin; pIg polyclonal immunoglobulin
aFreelite assay, The Binding Site Group, Birmingham, UK
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(< 1 g/L) in one patient, and the SFLC ratio was elevated
at 2.09 in one other patient, with no evidence for persist-
ing monoclonal gammopathy in the remaining two
patients.
Discussion and conclusions
We report four patients with noninfectious mixed CGN
in whom MGUS was diagnosed using conventional
methods for paraprotein detection [16, 26]. One in every
five patients assessed in our cohort of noninfectious
mixed CGN was found to have MGUS, although the
true incidence of any such association remains uncertain
owing to a paucity of data in the major published series
[11, 27, 28]. This is partly because of limited biochemical
analysis in previous studies, which have focussed exclu-
sively on immunofixation of the cryoprecipitate. Whilst
this remains a highly sensitive technique for detecting
circulating mIg (> 0.05 g/L) in patients with type 1 or 2
cryoglobulinaemia, for example in comparison to SPEP
(> 0.5 g/L) [29], its role in diagnosis of MGUS is not
established. Thus all 20 patients in one series of nonin-
fectious mixed CGN were shown to have type 2 CGN,
with monoclonal gammopathy reported in 18 patients,
yet without reference to cryoglobulin quantitation, SPEP,
SIFE, SFLC, UPEP or UIFE [28]. These data were also
not available in a recent series of 80 patients with
noninfectious mixed CGN comprising 75 patients with
type 2 CGN [11].
Conditions other than MGUS could potentially account
for the development of mixed CGN in our cohort. pSS,
which represents the commonest cause of mixed cryoglo-
bulinaemia/CGN after HCV infection [8, 9, 11, 27, 28],
was present in three of our four patients (conforming to
current EULAR/ACR criteria [30]), including both cases
of confirmed type 2 CGN. pSS involves a disease process
of continuous polyclonal B cell activation, with malignant
transformation of B cell clones in some cases, based on
the increased incidence of lymphoma in patients with pSS
[31, 32] (especially those with mixed cryoglobulinaemia
[33, 34]). Of note, MGUS may also be more common in
patients with pSS, and may confer an increased risk of de-
veloping lymphoma [35, 36] or myeloma [37]. It is there-
fore surprising that, prior to our study, coexistence of pSS
and MGUS has not been reported in noninfectious mixed
CGN. The additional finding in one of these patients of
cholangiocarcinoma is also novel, although other solid
organ malignancies have previously been reported in pa-
tients with noninfectious mixed CGN [38]. The one pa-
tient in our cohort who was confirmed as having type 3
CGN and who did not have pSS (Patient 3), was one of
three cases in which only a very small monoclonal band
(< 1 g/L) was identified. These observations raise import-
ant questions regarding the underlying pathophysiological
Table 4 Bone marrow aspirate and trephine
Patient Trephine Aspirate
Cellularity Immunohistochemistry Lymphoid cells
(5–20%)
Flow
cytometryPlasma cells (< 5%) Lymphoid aggregates
1 Normal < 5% One small 16% Normal
2 Normal < 5% Two small 9% Normal
3 Mildly hypercellular < 5% None 9% Normal
4 Normal < 5% None 5% Not assessed
Table 5 Treatment and last follow-up
Patient Treatment
received
Recurrent
vasculitis
Urine PCR
(< 30mg/
mmol)
Serum
creatinine
(μmol/L)
eGFRa (mL/
min per
1.73 m2)
Serum
cryoglobulin
C3 (0.9–
1.8 g/L)
C4 (0.16–
0.5 g/L)
Paraprotein Follow up
duration (Years)SPEP/
SIFE
SFLCb κ/λ
(0.26–1.65)
Spot
UPEP/
UIFE
1 CS/PE/
CYC
No 41 62 90 Neg 1.08 0.18 Neg 0.95 Neg 1.5
2 CS/PE/
CYC/AZA
No 24 159 30 Neg 0.93 0.25 Neg 1.29 Neg 2
3 CS/PE/
RTX
Yes 165 168 38 Neg 0.84 < 0.03 IgM-κ
(< 1 g/L)
1.47 Neg 5
4 CS/CYC/
RTX/MS
No 302 106 51 Neg 1.55 < 0.03 Neg 2.09 Neg 11
PCR protein creatinine ratio; eGFR estimated glomerular filtration rate; SPEP/SIFE serum protein electrophoresis/immunofixation; SFLC serum free light chains; κ
kappa; λ lambda; CS corticosteroids; PE plasma exchange; CYC cyclophosphamide; AZA azathioprine; RTX rituximab; MS mycophenolate sodium
a MDRD
b Freelite, UK
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processes responsible for noninfectious mixed CGN in the
setting of multiple possible aetiologies, and the need for
robust biochemical analysis as part of future studies, be-
fore causation should be attributed principally to MGUS.
It remains unclear from our study whether the identi-
fication of MGUS in a patient with noninfectious mixed
CGN provides any guide to treatment and prognosis. A
designation of MGRS implies the need for clonally tar-
geted therapies to be considered, with the primary aim
of improving renal outcomes [24]. Evidence for anticlo-
nal therapy in patients with noninfectious mixed CGN
consists largely of retrospective studies of rituximab,
mostly in patients with type 2 CGN involving a mono-
clonal IgM-κ component [11, 27, 28, 39]. As in previous
series of noninfectious mixed CGN [11, 27], our patients
received multiple therapies including rituximab but also
conventional immunosuppressive agents [11, 27]. Out-
comes were generally favourable, and of the two patients
with chronic kidney disease stage 3B at last follow-up,
both had shown significant (25–40%) interstitial fibrosis
on pre-treatment biopsies (potentially due to pSS-
associated interstitial nephritis in one of these cases).
Given previously reported, larger cohorts of noninfec-
tious mixed CGN showing ESKD rates of 9–10% at 4
years [11, 28], our study possibly indicates that MGUS
does not always confer a treatment-resistant course. No
patient in our series received bortezomib, for which a
single instance of use in refractory noninfectious mixed
CGN is reported, in a patient with type 2 CGN and a
monoclonal IgM-κ component, but no detectable mono-
clonal band on SPEP [40].
In conclusion, our study shows conclusively that
MGUS may be present in a subset of patients with non-
infectious mixed CGN. Even where this is the case, how-
ever, a designation of MGRS for cases of type 2 CGN
may be open to question, given the observation of po-
tential aetiologies for noninfectious mixed CGN other
than MGUS.
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